When was Fermentalg founded?

Fermentalg was founded in 2005 and raised its 1st funding round 6 years after it was founded.

Where is Fermentalg located?

Fermentalg is headquartered in Libourne, France.

How many employees does Fermentalg have?

As of Sep 30, 2026, the latest employee count at Fermentalg is 84.

Is Fermentalg a funded company?

Fermentalg is a funded company, having raised a total of $30.3M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jan 24, 2011.

When was the latest funding round of Fermentalg?

Fermentalg's latest funding was a $***** Post IPO round on Dec 20, 2021, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In France, the Life Sciences Platforms and Tools sector has seen $42M in funding in 2026 to date.

Where does Fermentalg rank among its competitors?

Fermentalg ranks 22nd amongst 2158 active competitors, of which 487 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was One Biosciences, which secured $3.76M in Sep, 2026.

Who are the top competitors of Fermentalg?

Fermentalg's top competitors include Antheia, Synthego and Axol Bioscience. Among them, One Biosciences secured the most recent funding round in September, 2026.

Fermentalg - 2026 Company Profile, Team, Funding & Competitors

Fermentalg is a public company based in Libourne (France), founded in 2005 by Pierre Calleja. It operates as an Innovating with algae for sustainable solutions in nutrition and environmental impact. Fermentalg has raised $30.3M in funding from investors like Demeter, CEA Investissement and Ace Management. The company has 2158 active competitors, including 487 funded and 328 that have exited. Its top competitors include companies like Antheia, Synthego and Axol Bioscience.

Company Details

Innovating with algae for sustainable solutions in nutrition and environmental impact. The company focuses on harnessing the power of microalgae to create a range of sustainable products. These include vegan omega , natural colors, natural antioxidants, and proteins for aquafeed and pet food. The company is committed to sustainability, demonstrated through certifications and a focus on social responsibility. Their approach includes screening strains, fermentation, and industrial scale-up. The company's work extends to environmental solutions through CarbonWorks, reflecting a commitment to a greener future. They offer solutions in nutrition and environmental impact, positioning themselves as a key player in the bio-based industry. The company is dedicated to research, development, and the application of microalgae across various sectors.

Website: www.fermentalg.com/
Social

Key Metrics

Founded Year

2005

Location

Libourne, France

Stage

Public

Total Funding

$30.3M in 5 rounds

Latest Funding Round

Post IPO, Dec 20, 2021, $*****

Investors

Demeter & 15 more

Ranked

22^nd among 2158 active competitors

Employee Count

84 as on Sep 30, 2026

Investment & Acquisitions

CarbonWorks

Similar Companies

Antheia & 2831 more

Exit Details

Public

View Fermentalg's full profile

Fermentalg got listed on Apr 16, 2014.

Click here to take a look at Fermentalg's IPO in detail

Fermentalg has raised a total funding of $30.3M over 5 rounds. Its first funding round was on Jan 24, 2011. Its latest funding round was a Post IPO round on Dec 20, 2021 for $*****. 1 investor participated in its latest round. Fermentalg has 16 institutional investors.

Here is the list of recent funding rounds of Fermentalg:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 20, 2021	6997859	Post IPO	5696500	1628172	4577760	9863412
Apr 16, 2014	9475202	Post IPO	1473699	7463028	9794226	Galia Gestion
Sep 23, 2013	3304599	Series B	1645206	2081871	Smalt Capital & 1 more	Sofiproteol & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Fermentalg's funding rounds and investors

The founders of Fermentalg is Pierre Calleja.

Here are the details of Fermentalg's key team members:

Pierre Calleja: Founder, CEO & Chairman of Fermentalg.

View details of Fermentalg's Founder profiles and Board Members

Fermentalg's employee count trend

Fermentalg has 84 employees as of Sep 26. Here is Fermentalg's employee count trend over the years:

Uncover Fermentalg's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Fermentalg include Antheia, Synthego and Axol Bioscience. Here is the list of Top 10 competitors of Fermentalg, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	68/100
2nd	Synthego 2012, Redwood City (United States), Acquired	Manufacturer of custom CRISPR gene editors and molecular biology reagents	$460M	8VC, Perceptive Advisors & 31 others	67/100
3rd	Axol Bioscience 2013, Cambridge (United Kingdom), Series A	Provider of human cells, reagents, and reprogramming services	$13.3M	Calculus Capital, Scottish Enterprise & 13 others	65/100
4th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
5th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 15 others	65/100
6th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
7th	Avalyn Pharma 2011, Seattle (United States), Public	Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis	$389M	Perceptive Advisors, Norwest & 22 others	64/100
8th	enGene 1999, Saint laurent (Canada), Public	Developer of oral non-viral gene therapy platform	$54M	Hercules Capital, Lumira Ventures & 15 others	63/100
9th	Watchmaker Genomics 2018, Boulder (United States), Series A	Developer of gene-editing technology	$48.3M	Decheng Capital, Eclipse	63/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 7 others	63/100
22nd	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Ace Capital Partners, Demeter & 14 others	60/100